Be A Freedom Fighter · Bill Library

HR 10649 — Safe Disposal of Opioids Act of 2026

Freedom score: -2 (scale −10 to +10)

Sponsor: · Latest action: ()

Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index

Findings — 5 highlighted provisions

Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.

  1. Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right See in text ↓
  2. Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text See in text ↓
  3. Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act See in text ↓
  4. Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections See in text ↓
  5. Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill See in text ↓

Full text (introduced version)

6 of 7 text blocks highlighted. Source: GovInfo, fetched cached.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 10649 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 10649 To amend the Comprehensive Addiction and Recovery Act of 2016 to authorize the Attorney General, in coordination with the Administrator of the Drug Enforcement Administration, the Secretary of Health and Human Services, and the Director of the Office of National Drug Control Policy, to award grants to covered entities to establish or maintain disposal sites for unwanted prescription medications, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES October 1, 2026 Ms. Bonamici (for herself and Mr. Moore of West Virginia) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Comprehensive Addiction and Recovery Act of 2016 to authorize the Attorney General, in coordination with the Administrator of the Drug Enforcement Administration, the Secretary of Health and Human Services, and the Director of the Office of National Drug Control Policy, to award grants to covered entities to establish or maintain disposal sites for unwanted prescription medications, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Safe Disposal of Opioids Act of 2026''.

SEC. 2. GRANTS FOR DISPOSAL SITES FOR UNWANTED PRESCRIPTION MEDICATIONS.

Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right

Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text

Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act

Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections

Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill

Section 203 of the Comprehensive Addiction and Recovery Act of 2016 (21 U.S.C. 822a) is amended by adding at the end the following:

Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right

Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text

Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act

Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections

Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill

``(c) Grants for Disposal Sites for Unwanted Prescription Medications.--

Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right

Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text

Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act

Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections

Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill

``(1) Grants.-- ``(A) Awards.--In carrying out subsection (b), the Attorney General shall award grants to covered entities to establish or maintain disposal sites for unwanted prescription medications. ``(B) Limitation.--Of the total amount of awards under subparagraph (A) for a fiscal year, the Attorney General shall not award more than 10 percent to covered entities that are-- ``(i) State, local, or tribal law enforcement agencies; or ``(ii) manufacturers, distributors, or reverse distributors of prescription medications.

Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right

Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text

Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act

Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections

Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill

``(2) Discounts for eligible patients.-- ``(A) In general.--The Secretary of Health and Human Services shall establish a mechanism by which amounts paid by an eligible patient for an active opioid are discounted at time of payment or purchase to ensure that such patient does not pay any amount attributable to a fee under paragraph (3), with as little burden on the patient as possible. ``(B) Definition.--For purposes of subparagraph (A), the term `eligible patient' means-- ``(i) a patient for whom any active opioid (as so defined) is prescribed to treat pain relating to cancer or cancer treatment; ``(ii) a patient participating in hospice care; and ``(iii) in the case of the death or incapacity of a patient described in clause (i) or (ii) or any similar situation as determined by the Secretary of Health and Human Services, the appropriate family member, medical proxy, or similar representative or the estate of such patient.

Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right

Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text

Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act

Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections

Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill

``(3) Fees.-- ``(A) In general.--There is hereby imposed on the sale of any active opioid by the manufacturer, producer, or importer a fee equal to 1 cent per 100 milligrams so sold. ``(B) Special rules.-- ``(i) Definition.--In this paragraph, the term `active opioid'-- ``(I) means any controlled substance (as defined in section 102 of the Controlled Substances Act, as in effect on the date of the Safe Disposal of Opioids Act of 2026) which is opium, an opiate, or any derivative thereof; and ``(II) excludes any prescribed drug which is used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. ``(ii) Exclusion of other ingredients.--In the case of a product that includes an active opioid and another ingredient, subparagraph (A) shall apply only to the portion of such product that is an active opioid.

Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right

Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text

Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act

Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections

Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill

``(4) Authorization of appropriations.--For fiscal year 2027 and each subsequent fiscal year, there is authorized to be appropriated to carry out this subsection an amount not to exceed the aggregate amount of the fees collected pursuant to paragraph (3).''. <all>

Findings source: bill-scores-v2-batch55-findings-2026-11-15.md. Highlights come only from that file; no finding, score, or provision was invented for this page.

What you can do

Contact your U.S. Representative and Senators about this bill.

Find your Representative Contact your Senators

Spot an error on this page? Report it.